Survival Benefits of Statins in Breast Cancer Patients (SBSBC)

  • End date
    Jun 28, 2024
  • participants needed
  • sponsor
    Peking Union Medical College Hospital
Updated on 9 February 2022
breast cancer
invasive breast cancer


In this study, we compared the survival benefit of breast cancer patients with dyslipidemia (low and medium risk of ASCVD). The control group used dietary intervention instead of statins intervention. The main endpoint was 5 years DFS. The subjects were breast cancer patients.


A randomized, open, blank controlled, single-center clinical trial was conducted to compare the survival benefits of statins in breast cancer patients with dyslipidemia (low and medium risk of ASCVD). The control group used dietary intervention instead of statins. The main endpoint was 3 and 5 years DFS. The subjects were breast cancer patients. In this study, 348 patients were randomly divided into two groups according to patients' wishes and written informed consent. The experimental group: control group = 1:1. Subjects were screened and administered continuously until the disease progressed and the toxicity was intolerable. Informed consent was withdrawn or the researcher decided that the drug must be discontinued.

Condition Breast Cancer Female
Treatment statins, Dietary intervention group (control group)
Clinical Study IdentifierNCT03971019
SponsorPeking Union Medical College Hospital
Last Modified on9 February 2022


Yes No Not Sure

Inclusion Criteria

Diagnosed as invasive breast cancer, it has been treated surgically, confirmed by histology, cytology or imaging
Female patients (35-75 years old)
The low-risk patients with ASCVD are detailed in Annex 1
Signed written informed consent approved by IRB or IEC

Exclusion Criteria

The subjects were pregnant or lactating
Pregnancy test positive (urine or serum) in women with potential pregnancy within 7 days before administration
Other invasive tumors (including the second primary breast cancer) may affect the evaluation of outcomes and the compliance of schemes, but subjects who have been cured and survived disease-free for at least five years can be selected
Patients with chronic underlying liver diseases who have abnormal liver function and/or clinical manifestations
Serum total bilirubin > 2.5 ULN; or INR > 1.5 although there was no increase
in bilirubin Serum ALT or AST > 3 ULN; Alkaline phosphatase > 2.5 ULN
Elevated ALT or AST may gradually recover, but with progressively increased
fatigue, nausea and vomiting, fever, right upper abdominal pain or tenderness
\. Extremely high risk ASCVD patients Including acute coronary syndrome
(ACS), stable coronary heart disease, revascularization, ischemic
cardiomyopathy, ischemic stroke, transient ischemic attack, peripheral
atherosclerosis, etc
\. High-risk ASCVD patients (in accordance with one of the following
LDL-C>4.9 mmol/L or TC>7.2 mmol/L Diabetic patients with 1.8 mmol/L < LDL-C <
9 mmol/L (or) 3.1 mmol/L < TC < 7.2 mmol/L and age < 40 years
The 10-year risk of ASCVD was moderate and younger than 55 years old. The
remaining life risk was assessed. Those with any of the following two or more
risk factors are defined as high risk
Systolic or diastolic blood pressure (> 160 mmHg) or (> 100 mmHg)
Non-HDL-C>5.2 mmol/L (200 mg/dl)
HDL-C < 1.0 mmol/L (40 mg/dl)
BMI>28 kg/m2 Smoking 7. In the abnormal group of simple TG (triglyceride), TG (> 5.7 mmol/L) 8. Other serious diseases, including
Congestive heart failure (NYHA grade II, III, IV); dyspnea at rest or
requiring oxygen therapy; severe infection; uncontrolled diabetes mellitus
\. If there are serious mental or mental disorders, it is estimated that the
subjects'compliance to participate in this study is not strong
\. Drug allergies to research drugs are known
\. Participated in other drug clinical trials in the past 30 days
\. Failure to complete at least one cycle of clinical trials based on this
protocol, and failure to evaluate safety and effectiveness
\. Serious violation of this study program, not in accordance with the
prescribed dose, method and course of treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note